Mapping iron levels in the brain with a noninvasive scan could help identify multiple sclerosis patients at higher risk of future physical disability.
A study led by researchers at the University of Buffalo has shown that an advanced MRI technique can help to identify patients with multiple sclerosis (MS) who are at an increased risk of developing a physical disability.
In multiple sclerosis, the immune system mistakenly attacks and harms myelin, which is the "sheath" that protects axons (or the projection that links nerve cells to one another and lets them communicate). This can result in muscle weakness, fatigue, coordination problems, and chronic pain.
A potential new therapeutic target for multiple sclerosis has now been identified in a new study conducted by researchers at the University of Alberta and McGill University, both in Canada. The results are published in the journal JCI Insight.
Multiple sclerosis: Have researchers found a key to prevention?
Multiple sclerosis is an autoimmune disease wherein the immune system turns against healthy cells in the central nervous system, attacking myelin, or the "coating" around nerve cells. Scientists now investigate a key factor that may influence the chance of developing this condition.
A new study from Kaiser Permanente investigates whether or not certain nutritional changes — specifically, eating more fish and taking omega-3 supplements — could decrease the risk of multiple sclerosis.
I samarbejde med Sclerose Info arrangerer Rehabrejser og Vita Sana, fysioterapi i Spanien et spændende ophold i Sydspanien. Opholdet bliver krydret med input omkring træning, kost, afspænding og livs-stil. Til opholdet kan du få tilskud fra Sygesikringen med en henvis-ning til fysioterapi.
Opholdet er fra tirsdag d. 31/10 – tirsdag d. 7/11 2017
Kontakt Margit på tlf: 2888 0591 eller Per på tlf: 5116 3265 fra Rehabrejser.
Vita Sanas danske fysioterapeut, Jacob Lindgreen kan du kontakte på tlf: +34 638 592 498 eller mail: email@example.com
Som altid er Sclerose.info’s Facebook gruppe aktiv og med en god debat – men det er vigtigt at huske på vi er alle forskellige.
Sclerose.infos Facebook gruppe vokser stødt og roligt. Vi bliver flere i debatten og flere stemmer, og som en naturlig ting når der bliver flere, bliver der også flere forskelligheder.
Det er vigtigt at vi huske på – og at vi husker hinanden på – at der skal være plads til forskellighed. Der skal være plads til holdninger som man måske ikke lige selv er enig i eller ikke kan identificere sig med. Det er basis for en god og sund debat.
Uenighed er IKKE dårligt overhovedet. Det ville da være kedeligt hvis vi alle er enige !!
MEN … som det er i det virkelige liv, sådan er det også i cyberspace, i den virtuelle verden som Facebook er en del af – man skal tale ordentligt til
Man skal også skrive ordentligt til hinanden – trods uenighed.
Tonen i dit indslag SKAL være god.
Vi har i administrationen (admin gruppen på Facebook) fået en del henvendelser om forskellige indlæg hvor at tonen er for grov, og folk finder det ubehageligt.
Derfor – nu skærper vi tonen i gruppen. Admin har fået af vide at vi ikke vil acceptere flere grove indlæg. Det nytter ikke noget.
Facebook gruppen er vigtig for os som scleroseramte hvor vi skal kunne dele erfaringer , fortælle om vores liv, behandlinger, råd osv osv.
MEN – det skal foregå ordentligt. Grove indlæg og tråden vil i fremtiden blive slettet.
Facebook bruppens admin agere efter pålagt direktiv fra foreningen.
Med højere indtag af omega-3 polyumættede fedtsyrer har man nedsat for en klinisk diagnose af centralnervesystemet. Demyelinisering.
Resultater fra Autoimmune Study
Higher intake of omega-3 polyunsaturated fatty acids is associated with a decreased risk of a first clinical diagnosis of central nervous system demyelination: Results from the Ausimmune Study
Background: There is contradictory evidence for a role of dietary fat in risk of multiple sclerosis (MS).
Objectives: To examine the association between usual fat intake (total, saturated, monounsaturated (MUFA), polyunsaturated (PUFA), omega-3 and omega-6) and risk of a first clinical diagnosis of CNS demyelination (FCD).
Methods: Multi-centre incident case-control study in four regions of Australia during 2003–2006. Cases were aged 18–59 years and had a FCD; controls were matched to a case on age, sex and location. Dietary data were collected using a validated food frequency questionnaire.
Results: In 267 cases and 517 controls with dietary data, higher intake (per g/day) of omega-3 PUFA (adjusted odds ratio, AOR=0.61 (95% CI 0.40–0.93)), and particularly that derived from fish (AOR=0.54 (95% CI 0.31–0.93)) rather than from plants (AOR=0.75 (95% CI 0.39–1.43)) was associated with a decreased risk of FCD. Total fat intake and intake of other types of fat were not associated with FCD risk.
Conclusions: There was a significant decrease in FCD risk with higher intake of omega-3 PUFA, particularly that originating from fish. There was no evidence to indicate that the intake of other types of dietary fat or fat quantity in the previous 12 months was associated with an altered risk of FCD.
National Centre for Epidemiology and Population Health, The Australian National University, Australia
The University of Canberra, Australia
Ingrid van der Mei
Menzies Institute for Medical Research, Australia
Murdoch Childrens Research Institute, Royal Children’s Hospital, University of Melbourne, Australia
National Centre for Epidemiology and Population Health, The Australian National University, Australia
for the Ausimmune Investigator Group*
National Centre for Epidemiology and Population Health, The Australian National University, Canberra, Australia 2600.
Kan bedre søvn gøre at du forbedre dine kognitive problemer?
Nogle scleroseramte har problemer med hukommelse, opmærksomhed, fokus eller konigtion. Ny forskning viser nogle af disse ting kan stamme fra dårlig søvn - at man sover dårligt.
In MS, can better sleep improve cognition?
- June 13, 2016
- University of Michigan Health System
- People with multiple sclerosis often have trouble with memory, attention and mental processing. New research shows some of these issues could stem from sleep disorders.
Multiple sclerosis looks different from person to person. In many individuals, though, the difficulty in maintaining a sense of self and in keeping up intellectually can be the disease's most devastating manifestations.
With this in mind, University of Michigan researchers are exploring a new way to improve cognitive issues, such as memory, attention and mental processing in MS patients: by examining sleep.
People with MS face an elevated risk of obstructive sleep apnea (OSA), a disorder in which the throat collapses during sleep, causing the patient to repeatedly stop breathing for periods of 10 seconds or longer throughout the night. OSA can lead to a decline in mental functioning.
A U-M pilot study published in Sleep is the first to find an association between sleep apnea severity and cognitive dysfunction in patients with MS.
"Since obstructive sleep apnea is a treatable condition that is also commonly seen in MS, we wondered, 'What if some of the thinking and processing difficulties that MS patients experience do not stem directly from the MS itself, but from the effects of sleep apnea or other sleep problems?'" says Tiffany Braley, M.D., M.S., the principal investigator and co-first author of the study, and an assistant professor of neurology at U-M.
MS affects nearly half a million Americans and is the leading non-traumatic cause of neurological disability among young adults.
Braley's team studied 38 adults with MS who had questions about their sleep or cognition. The patients performed seven cognitive tests, which included tasks of word list recall, calculation, and reproducing figures and pictures.
They also spent a night in the Michael S. Aldrich Sleep Disorders Laboratory for polysomnography, an overnight sleep test. Thirty-three of the 38 patients met the criteria for OSA.
"Multiple measures of sleep apnea severity directly correlated with poorer performance on several cognitive tests," said co-first author Anna Kratz, Ph.D., a clinical psychologist and assistant professor of physical medicine and rehabilitation. "In particular, problems with attention and multiple aspects of memory, including memory for words and images, and working memory, which plays a role in problem solving and decision making, were all associated with poorer sleep."
Apnea severity measures accounted for between 11 and 23 percent of the variance in cognitive test performance. The investigators also observed relationships between other sleep quality measures and poor cognitive performance.
"Current MS treatments can prevent further neurological damage, but do little to help existing MS symptoms and damage," Braley says. "Our focus on sleep is part of a larger collaborative initiative to identify previously overlooked but nonetheless treatable conditions that could be affecting patients with MS. Identifying and successfully treating conditions like OSA could help us find new ways to improve the cognitive function in MS."
Now, the researchers will replicate their findings in a larger sample of MS patients, and treat those patients diagnosed with obstructive sleep apnea with positive airway pressure therapy (CPAP), the first-line treatment for OSA. The new clinical trial, led by Braley and funded by the National Multiple Sclerosis Society, will investigate whether cognitive function in MS patients improves when sleep apnea is treated. In the meantime, the investigators want to inspire more conversations in the neurology clinic.
"We hope neurologists will ask their patients with MS about sleep, and the patient should be encouraged to openly discuss sleep concerns with their neurologist," says Neeraj Kaplish, M.D., assistant professor of neurology and medical director of the U-M Sleep Laboratories.
"Given the high prevalence of treatable sleep problems in MS patients, and the fact that many patients with MS rate fatigue as one of their most bothersome symptoms, physicians should have a low threshold to refer MS patients who report sleep disturbances to sleep specialists," says last author Ronald Chervin, M.D., M.S., professor of neurology and director of U-M Sleep Disorders Center.
The research was funded in part by the National Center for Advancing Translational Sciences of the National Institutes of Health, the University of Michigan Sleep Disorders Center and the National Institute of Arthritis and Musculoskeletal and Skin Diseases.
The above post is reprinted from materials provided by University of Michigan Health System. Note: Materials may be edited for content and length